Overview

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

Status:
Completed

Trial end date:
2006-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Enoxaparin
Enoxaparin sodium